PPMD Community

On October 23, 2012, PPMD hosted a webinar with Sarepta to discuss of the 48 Week dystrophin and 6-minute walk test (6MWT) data from the Phase IIb extension study in Duchenne as well as next steps for the eteplirsen program. Chris Garabedian, President and CEO of Sarepta Therapeutics presented the data and answered submitted questions.

Rating:
  • Currently 0/5 stars.

Views: 516

Favorite of 1 person

Related Videos

Comment by Melissa Meller on November 19, 2012 at 11:51am

Thanks you for posting this! My hand couldn't keep up with the notes! :) 

Comment

You need to be a member of PPMD Community to add comments!

Join PPMD Community

© 2017   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service